Theolytics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 33

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2.59M

  • Investors
  • 8

Theolytics General Information

Description

Operator of the phenotypic screening platform intended to harness viruses to combat cancer. The company focuses on developing category-changing cancer therapies in the form of oncolytic viruses and its phenotypic screening approach helps the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimized for a chosen patient population, allowing doctors to deliver innovative care to patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • The Sherard Building
  • Edmund Halley Road Oxford Science Park
  • Oxford OX4 4DQ
  • England, United Kingdom
+44 01865
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • The Sherard Building
  • Edmund Halley Road Oxford Science Park
  • Oxford OX4 4DQ
  • England, United Kingdom
+44 01865

Theolytics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Theolytics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 02-Sep-2024 $2.59M Completed Clinical Trials - Phase 1
7. Later Stage VC 17-Apr-2024 Completed Clinical Trials - Phase 1
6. Grant 01-May-2022 Completed Pre-Clinical Trials
5. Early Stage VC (Series A2) 08-Jul-2021 Completed Pre-Clinical Trials
4. Grant 01-Nov-2020 Completed Pre-Clinical Trials
3. Accelerator/Incubator 15-May-2020 Completed Pre-Clinical Trials
2. Seed Round 15-Dec-2017 $3.34M $3.34M Completed Startup
1. University Spin-Out 01-Jan-2017 Completed Startup
To view Theolytics’s complete valuation and funding history, request access »

Theolytics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2
Series A1
Series A
Series A 4,192 $0.001260 $390.65 $390.65 1x $390.65 3.22%
Ordinary 10,000 $0.001260 $315.04 $315.04 1x $315.04 7.68%
To view Theolytics’s complete cap table history, request access »

Theolytics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of the phenotypic screening platform intended to harness viruses to combat cancer. The company focuses on devel
Drug Discovery
Oxford, United Kingdom
33 As of 2024

London, United Kingdom
 

Macclesfield, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Theolytics Competitors (3)

One of Theolytics’s 3 competitors is MiNA Therapeutics, a Venture Capital-Backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MiNA Therapeutics Venture Capital-Backed London, United Kingdom
Redx Pharma Formerly VC-backed Macclesfield, United Kingdom
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
You’re viewing 3 of 3 competitors. Get the full list »

Theolytics Patents

Theolytics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202401712-D0 Adenoviruses Pending 08-Feb-2024
GB-202401719-D0 Adenoviruses Pending 08-Feb-2024
GB-202401729-D0 Adenoviruses Pending 08-Feb-2024
GB-202401715-D0 Adenoviruses Pending 08-Feb-2024
GB-202319693-D0 Adenoviruses Pending 20-Dec-2023
To view Theolytics’s complete patent history, request access »

Theolytics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Theolytics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Sound Bioventures Venture Capital Minority
Epidarex Capital Venture Capital Minority
M Ventures Corporate Venture Capital Minority
Taiho Ventures Corporate Venture Capital Minority
Innovate UK Accelerator/Incubator
You’re viewing 5 of 8 investors. Get the full list »

Theolytics FAQs

  • When was Theolytics founded?

    Theolytics was founded in 2017.

  • Where is Theolytics headquartered?

    Theolytics is headquartered in Oxford, United Kingdom.

  • What is the size of Theolytics?

    Theolytics has 33 total employees.

  • What industry is Theolytics in?

    Theolytics’s primary industry is Drug Discovery.

  • Is Theolytics a private or public company?

    Theolytics is a Private company.

  • What is Theolytics’s current revenue?

    The current revenue for Theolytics is .

  • How much funding has Theolytics raised over time?

    Theolytics has raised $46.2M.

  • Who are Theolytics’s investors?

    Sound Bioventures, Epidarex Capital, M Ventures, Taiho Ventures, and Innovate UK are 5 of 8 investors who have invested in Theolytics.

  • Who are Theolytics’s competitors?

    MiNA Therapeutics, Redx Pharma, and Adaptimmune Therapeutics are competitors of Theolytics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »